Using EEG-guided basket and umbrella trials in psychiatry: a precision medicine approach for cognitive impairment in schizophrenia
- 1University of California, San Diego, United States
- 2VA San Diego Healthcare System, United States
Due to advances over the last several decades, many fields of medicine are moving towards a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogues in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.
Keywords: Schizophrenia, mismatch negativity (MMN), biomarker, Clinical Trial, cogntive impairment
Received: 30 Jul 2018;
Accepted: 15 Oct 2018.
Edited by:Stefan Borgwardt, Universität Basel, Switzerland
Reviewed by:Christina Andreou, Universitäre Psychiatrische Kliniken Basel, Switzerland
Amineh Koravand, University of Ottawa, Canada
Copyright: © 2018 Joshi and Light. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Gregory Light, University of California, San Diego, San Diego, United States, email@example.com